(AVXL) Anavex Life Sciences - Overview
Stock: Therapeutic Compounds, Neurological Indications, Clinical Candidates
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.7% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.56 |
| Alpha | -71.23 |
| Character TTM | |
|---|---|
| Beta | 1.126 |
| Beta Downside | 0.595 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.12% |
| CAGR/Max DD | -0.35 |
Description: AVXL Anavex Life Sciences January 25, 2026
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a U.S.-based biopharmaceutical firm focused on developing oral small-molecule therapies for central nervous system (CNS) disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Rett syndrome, and certain cancers. The company’s platform centers on sigma-1 receptor (SIGMAR1) modulation combined with muscarinic receptor activity to restore cellular homeostasis.
The lead candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a trial and is currently in a combined Phase 2b/3 study for AD (NCT05812345). As of the Q4 2025 earnings release, the trial reported a 4.2-point advantage on the ADAS-Cog13 scale versus placebo (p = 0.07) and a favorable safety profile, prompting the FDA to grant Fast Track designation in March 2025. Parallel studies include a Phase 2 proof-of-concept in PD dementia (N = 120) and a Phase 2/3 program in pediatric Rett syndrome (N = 80), both of which have met primary safety endpoints.
Beyond ANAVEX 2-73, the pipeline includes ANAVEX 3-71, a SIGMAR1/M1 muscarinic agonist that demonstrated disease-modifying effects in the 3xTg-AD mouse model, reducing amyloid-β and tau pathology by ~30 % and improving Morris water-maze performance. Preclinical data released in February 2026 suggest synergistic activity with existing cholinesterase inhibitors, positioning ANAVEX 3-71 for a potential combination trial in early AD.
Financially, AVXL reported $115 million in cash and equivalents at the end of 2025, providing runway through mid-2027 assuming current burn of ~$25 million per quarter. The CNS biotech sector has attracted $4.2 billion of venture capital in 2025, driven by growing investor confidence in sigma-1 receptor targets after positive Phase 2 outcomes from multiple peers. Given the modest market cap (~$350 million) and the advancing clinical data, the stock remains highly sensitive to trial readouts.
For a deeper, data-driven valuation perspective, consider reviewing AVXL’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA -14.88 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 > 3% & CFO -39.0m > Net Income -46.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.9m) vs 12m ago 2.25% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.06 > 6 (EBITDA TTM -33.5m / Interest Expense TTM 22.6m) |
Altman Z'' -15.00
| A: 0.91 (Total Current Assets 103.8m - Total Current Liabilities 8.95m) / Total Assets 103.8m |
| B: -3.68 (Retained Earnings -382.4m / Total Assets 103.8m) |
| C: -0.20 (EBIT TTM -23.8m / Avg Total Assets 119.7m) |
| D: -42.74 (Book Value of Equity -382.4m / Total Liabilities 8.95m) |
| Altman-Z'' Score: -52.23 = D |
What is the price of AVXL shares?
Over the past week, the price has changed by -12.77%, over one month by +2.24%, over three months by -44.59% and over the past year by -52.82%.
Is AVXL a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVXL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22 | 436.6% |
| Analysts Target Price | 22 | 436.6% |
| ValueRay Target Price | 3.3 | -19.8% |
AVXL Fundamental Data Overview February 05, 2026
P/B = 4.1345
Revenue TTM = 0.0 USD
EBIT TTM = -23.8m USD
EBITDA TTM = -33.5m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -102.6m USD (from netDebt column, last quarter)
Enterprise Value = 266.4m USD (369.0m + (null Debt) - CCE 102.6m)
Interest Coverage Ratio = -1.06 (Ebit TTM -23.8m / Interest Expense TTM 22.6m)
EV/FCF = -6.82x (Enterprise Value 266.4m / FCF TTM -39.0m)
FCF Yield = -14.65% (FCF TTM -39.0m / Enterprise Value 266.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.57 (Enterprise Value 266.4m / Total Assets 103.8m)
Interest Expense / Debt = unknown (Interest Expense 22.6m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -18.8m (EBIT -23.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.60 (Total Current Assets 103.8m / Total Current Liabilities 8.95m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 3.06 (negative EBITDA) (Net Debt -102.6m / EBITDA -33.5m)
Debt / FCF = 2.63 (negative FCF - burning cash) (Net Debt -102.6m / FCF TTM -39.0m)
Total Stockholder Equity = 99.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.75% (Net Income -46.4m / Total Assets 103.8m)
RoE = -46.79% (Net Income TTM -46.4m / Total Stockholder Equity 99.1m)
RoCE = -25.10% (EBIT -23.8m / Capital Employed (Total Assets 103.8m - Current Liab 8.95m))
RoIC = -18.98% (negative operating profit) (NOPAT -18.8m / Invested Capital 99.1m)
WACC = 10.06% (E(369.0m)/V(369.0m) * Re(10.06%) + (debt-free company))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.30%
Fair Price DCF = unknown (Cash Flow -39.0m)
EPS Correlation: 58.38 | EPS CAGR: 40.64% | SUE: 4.0 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-09-30): EPS=-0.48 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+11.1% | Growth Revenue=+0.0%
EPS next Year (2027-09-30): EPS=1.27 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+364.6% | Growth Revenue=+0.0%